Susan Silbermann is President and General Manager, Pfizer Vaccines. In this role, Silbermann oversees a global business of more than $4 billion in revenues and is responsible for the commercial development of a robust and active pipeline in both prophylactic and therapeutic vaccines.
Prior to this position, she was the regional president of Latin America within Pfizer’s Emerging Markets Business Unit. In this role, she managed Pfizer’s pharmaceutical operations in more than 20 countries and guided the business to reach revenues of more than $3 billion.
Silbermann began her career at Pfizer in 1988 as an intern in U.S. Marketing. She has served in various positions in the U.S. and international markets, including Marketing Director in Pfizer Italy, Vice President of U.S. Pharmaceutical Marketing and Senior Vice President of World Wide Commercial Development.
She is an active member of the Vaccine Policy Advisory Committee at Biotechnology Industry Organization (BIO) in Washington D.C. and holds a seat on the Vaccines CEO Roundtable at International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) in Geneva. She is an emeritus member of Pfizer’s Diversity Worldwide Leadership Council and recently stepped down as chair of the Global Women’s Council. In addition, Silbermann serves on the boards of advisors for Catalyst Inc. and on the corporate advisory board for the Johns Hopkins University Carey Business School.
Silbermann has a BS in biology and French from Tufts University, and a joint MBA/MA in international business and French studies from the Stern Graduate School of Business and the Institute of French Studies at New York University.